COMMUNIQUÉS West-GlobeNewswire

O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
20/02/2026
Data from the first in human study on O3R-5671’s potent TNFα inhibition Studies in ulcerative colitis and psoriasis to initiate in H2 2026 Leuven, Belgium. February 20, 2025 . Onco3R Therapeutics, a clinical-stage [...]
PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International
20/02/2026
Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market. The agreement marks PL BioScience’s first exclusive distribution partnership in Japan. Cell [...]
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
20/02/2026
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 [...]
Candel Therapeutics Announces Pricing of Public Offering
20/02/2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results
20/02/2026
Quarterly revenue of $748 million ; GAAP loss of ($0.20) /share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent [...]
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
19/02/2026
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for [...]
Magnesium Niacinamide Relief Topical Cream: What Consumers Are Researching Before Buying in 2026
20/02/2026
An informational overview of publicly available disclosures for Magnesium Niacinamide Relief (MagnesiumFreeze) — covering ingredients, company policies, and what consumers researching topical nerve discomfort and [...]
Sienna Reports Fourth Quarter 2025 Financial Results and Continues Platform Growth
19/02/2026
MARKHAM, Ontario, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and twelve months ended December 31, 2025. [...]
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
19/02/2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
19/02/2026
Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when [...]
Curaechoice and The Center for Pain to Deliver No-Cost Pain Management to Members Nationwide
19/02/2026
Curaechoice Members and Their Families Now Have Access to Comprehensive Pain Management Services from The Center for Pain, a Clearway Company, at $0 Cost. Birmingham, ALABAMA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
19/02/2026
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally [...]
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
19/02/2026
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
19/02/2026
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results
19/02/2026
Quarterly revenue of $748 million ; GAAP loss of ($0.20) /share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent [...]
STRATA Skin Sciences Confirms Nasdaq Delisting
19/02/2026
HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
19/02/2026
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD [...]
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
19/02/2026
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA [...]
Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors
19/02/2026
Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today [...]

Pages